Fusion Pharmaceuticals
compelling anti tumor activity across multiple tumor models and tumor sizes i with a single dose with alphas using the right | Fusion Pharmaceuticals
Company
Deck Type
IPO
Sector
Industry
Deck date
June 2020
Slide
20 of 49
Related slides by other companies
Alkermes
Results
June 2021
anti tumor activity in melanoma | Alkermes
Planet
SPAC
July 2021
compelling subscription multiple verticals | Planet
Kymera
Investor Day
December 2021
degrader first in class opportunity to address driven pathology across diverse indications first degrader against an undrugged target in the clinic profound single agent activity in liquid tumor and promising activity with anti in liquid and solid tumors clinical development strategy includes direct registrational path in pathway activated heme malignancies opportunity for expansion into solid tumors in combination with immune inhibitors | Kymera
Kymera
Investor Presentation
June 2023
objectives a a | Kymera
Other recent decks by Fusion Pharmaceuticals
See all presentations (4 decks)
Investor Presentation
January 2024
Investor Presentation
November 2023
Investor Presentation
August 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights